Louis A. Gaboury
Affiliations: | Université de Montréal, Montréal, Canada |
Area:
Pathology, Animal Physiology Biology, Oncology, Cell BiologyGoogle:
"Louis Gaboury"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Issac MSM, Yousef E, Tahir MR, et al. (2019) MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. Neoplasia (New York, N.Y.). 21: 1015-1035 |
Goyette MA, Duhamel S, Aubert L, et al. (2018) The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. Cell Reports. 23: 1476-1490 |
Duhamel S, Goyette MA, Thibault MP, et al. (2018) The E3 Ubiquitin Ligase HectD1 Suppresses EMT and Metastasis by Targeting the +TIP ACF7 for Degradation. Cell Reports. 22: 1016-1030 |
Medimegh I, Ayari H, Baraudi O, et al. (2018) Abstract P5-07-12: miR-34a as a prognostic biomarker for overall survival triple negative breast cancer within Tunisian patients Cancer Research. 78 |
Matsuda H, Campion CG, Fujiwara K, et al. (2017) HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma. Oncotarget. 8: 69559-69576 |
Chen L, Yuan Y, Kar S, et al. (2017) PPARγ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers. Molecular Cancer Therapeutics |
Williams V, Grosset AA, Zamorano Cuervo N, et al. (2017) Detection of IKKε by immunohistochemistry in primary breast cancer: association with EGFR expression and absence of lymph node metastasis. Bmc Cancer. 17: 356 |
Yousef EM, Furrer D, Laperriere DL, et al. (2017) MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc |
Grosset A, Poirier F, Gaboury L, et al. (2016) Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer. Plos One. 11 |
Grosset AA, Labrie M, Vladoiu MC, et al. (2016) Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets. Oncotarget. 7: 18183-18203 |